Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic study
Antimicrobial Agents and Chemotherapy · 2023
DOI: 10.1128/aac.00962-23 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Joseph Kado und 13 weiteren Autor:innen. Beteiligte Einrichtung: Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia. Hauptthemen laut MEDLINE: Rheumatic Fever, Rheumatic Heart Disease. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cure Kids (CK), University of Western Australia (UWA), Telethon Kids Institute (TKI).
Abstract (Originalsprache)
Since 1955, the recommended strategy for rheumatic heart disease (RHD) secondary prophylaxis has been benzathine penicillin G [BPG; 1.2 MU (900 mg)] injections administered intramuscularly every 4 weeks. Due to dosing frequency, pain, and programmatic challenges, adherence is suboptimal. It has previously been demonstrated that BPG delivered subcutaneously at a standard dose is safe and tolerable and has favorable pharmacokinetics, setting the scene for improved regimens with less frequent administration. The safety, tolerability, and pharmacokinetics of subcutaneous infusions of high-dose BPG were assessed in 24 healthy adult volunteers assigned to receive either 3.6, 7.2, or 10.8 MU (three, six, and nine times the standard dose, respectively) as a single subcutaneous infusion. The delivery of the BPG to the subcutaneous tissue was confirmed with ultrasonography. Safety assessments, pain scores, and penicillin concentrations were measured for 16 weeks post-dose. Subcutaneous infusion of penicillin (SCIP) was generally well tolerated with all participants experiencing transient, mild infusion-site reactions. Prolonged elevated penicillin concentrations were described using a combined zero-order (44 days) and first-order ( t 1/2 = 12 days) absorption pharmacokinetic model. In simulations, time above the conventionally accepted target concentration of 20 ng/mL (0.02 µg/mL) was 57 days for 10.8 MU delivered by subcutaneous infusion every 13 weeks compared with 9 days of every 4-weekly dosing interval for the standard 1.2 MU intramuscular dose (i.e., 63% and 32% of the dosing interval, respectively). High-dose SCIP (BPG) is safe, has acceptable tolerability, and may be suitable for up to 3 monthly dosing intervals for secondary prophylaxis of RHD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia.
- Medical School, University of Western Australia, Perth, Western Australia, Australia.
- Clinical Pharmacology and Toxicology Unit, PathWest, Western Australia, Australia.
- Department of Infectious Diseases, Fiona Stanley Hospital, Perth, Western Australia, Australia.
- Medical Imaging Department, Perth Children's Hospital, Nedlands, Western Australia, Australia.
- Department of Infectious Diseases, Royal Perth Hospital, Perth, Western Australia, Australia.
ORCID-Profile: Joseph Kado, Sam Salman, Robert M Hand, Kevin Batty, Laurens Manning
Förderung
- Cure Kids (CK)
- University of Western Australia (UWA)
- Telethon Kids Institute (TKI)
- DHAC | National Health and Medical Research Council (NHMRC)
Zitieren
APA
Kado, J., Salman, S., Hla, T. K., Enkel, S., Henderson, R., Hand, R. M., Hort, A., Page-Sharp, M., Batty, K., Moore, B. R., Bennett, J., Anderson, A., Carapetis, J., & Manning, L. (2023). Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic study. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00962-23
Vancouver
Kado J, Salman S, Hla TK, Enkel S, Henderson R, Hand RM, et al. Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic study. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.00962-23
BibTeX
@article{Kado2023,
author = {Kado, Joseph and Salman, Sam and Hla, Thel K and Enkel, Stephanie and Henderson, Robert and Hand, Robert M and Hort, Adam and Page-Sharp, Madhu and Batty, Kevin and Moore, Brioni R and Bennett, Julie and Anderson, Anneka and Carapetis, Jonathan and Manning, Laurens},
title = {Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic study},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2023},
doi = {10.1128/aac.00962-23}
}
EUVIMED